Effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls

American Journal of Physiology - Endocrinology and Metabolism

Volumn 300, Issue 6, 2011, Pages

  Donjacour, Claire E H M ^a   Aziz, N Ahmad ^a   Roelfsema, Ferdinand ^a   Frölich, Marijke ^a   Overeem, Sebastiaan ^b,c   Lammers, Gert Jan ^a   Pijl, Hanno ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

Author keywords

hydroxybutyrate; Hypocretin; Orexin

Indexed keywords

FAT; GROWTH HORMONE; OREXIN; OXYBATE SODIUM;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; BODY MASS; CATAPLEXY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; GROWTH HORMONE RELEASE; HORMONE BLOOD LEVEL; HUMAN; MALE; NARCOLEPSY; PRIORITY JOURNAL; SEX; SLEEP; WAIST HIP RATIO; WEIGHT REDUCTION;

ADULT; BODY COMPOSITION; BODY MASS INDEX; CATAPLEXY; DATA INTERPRETATION, STATISTICAL; ENTROPY; HUMAN GROWTH HORMONE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NARCOLEPSY; NEUROPEPTIDES; POLYSOMNOGRAPHY; SLEEP; SLEEP STAGES; SLEEP, REM; SODIUM OXYBATE; WAIST-HIP RATIO; WEIGHT LOSS;

EID: 79957662618     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00623.2010     Document Type: Article

References (50)

1. Arnulf I, Lin L, Zhang J, Russell IJ, Ripley B, Einen M, Nevsimalova S, Bassetti C, Bourgin P, Nishino S, Mignot E. CSF versus serum leptin in narcolepsy: is there an effect of hypocretin deficiency? Sleep 29: 1017-1024, 2006.
2. Besset A, Bonardet A, Billiard M, Descomps B, de Paulet AC, Passouant P. Circadian patterns of growth hormone and cortisol secretions in narcoleptic patients. Chronobiologia 6: 19-31, 1979.
3. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98: 437-451, 1999.
4. Clark RW, Schmidt HS, Malarkey WB. Disordered growth hormone and prolactin secretion in primary disorders of sleep. Neurology 29: 855-861, 1979.
5. Cuneo RC, Salomon F, McGauley GA, Sonksen PH. The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf) 37: 387-397, 1992.
6. Dahmen N, Bierbrauer J, Kasten M. Increased prevalence of obesity in narcoleptic patients and relatives. Eur Arch Psychiatry Clin Neurosci 251: 85-89, 2001.
7. Dahmen N, Engel A, Helfrich J, Manderscheid N, Lobig M, Forst T, Pfutzner A, Tonn P. Peripheral leptin levels in narcoleptic patients. Diabetes Technol Ther 9: 348-353, 2007.
8. Dahmen N, Tonn P, Messroghli L, Ghezel-Ahmadi D, Engel A. Basal metabolic rate in narcoleptic patients. Sleep 32: 962-964, 2009.
9. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 369: 499-511, 2007.
10. Fronczek R, Overeem S, Reijntjes R, Lammers GJ, van Dijk JG, Pijl H. Increased heart rate variability but normal resting metabolic rate in hypocretin/orexin-deficient human narcolepsy. J Clin Sleep Med 4: 248-254, 2008.
11. Gerra G, Caccavari R, Fontanesi B, Marcato A, Fertonani AG, Maestri D, Avanzini P, Lecchini R, Delsignore R, Mutti A. Flumazenil effects on growth hormone response to gamma-hydroxybutyric acid. Int Clin Psychopharmacol 9: 211-215, 1994.
12. Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benham CD, Taylor SG, Routledge C, Hemmati P, Munton RP, Ashmeade TE, Shah AS, Hatcher JP, Hatcher PD, Jones DN, Smith MI, Piper DC, Hunter AJ, Porter RA, Upton N. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA 96: 10911-10916, 1999.
13. Higuchi T, Takahashi Y, Takahashi K, Niimi Y, Miyasita A. Twentyfour- hour secretory patterns of growth hormone, prolactin, and cortisol in narcolepsy. J Clin Endocrinol Metab 49: 197-204, 1979.
14. Holl RW, Hartman ML, Veldhuis JD, Taylor WM, Thorner MO. Thirty-second sampling of plasma growth hormone in man: correlation with sleep stages. J Clin Endocrinol Metab 72: 854-861, 1991.
15. Husain AM, Ristanovic RK, Bogan RK. Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med 10: 661-663, 2009.
16. Iber C, Ancoli-Israel S, Chesson AL, Quan S. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifiations. Westchester, IL: American Academy of Sleep Medicine, 2007.
17. ICSD. International Classification of Sleep Disorders: Second Edition. Westchester, IL: American Academy of Sleep Medicine, 2005.
18. Johnson ML, Pipes L, Veldhuis PP, Farhy LS, Boyd DG, Evans WS. AutoDecon, a deconvolution algorithm for identification and characterization of luteinizing hormone secretory bursts: description and validation using synthetic data. Anal Biochem 381: 8-17, 2008.
19. Johnson ML, Pipes L, Veldhuis PP, Farhy LS, Nass R, Thorner MO, Evans WS. AutoDecon: a robust numerical method for the quantification of pulsatile events. Methods Enzymol 454: 367-404, 2009.
20. Kok SW, Meinders AE, Overeem S, Lammers GJ, Roelfsema F, Frolich M, Pijl H. Reduction of plasma leptin levels and loss of its circadian rhythmicity in hypocretin (orexin)-deficient narcoleptic humans. J Clin Endocrinol Metab 87: 805-809, 2002.
21. Kok SW, Overeem S, Visscher TL, Lammers GJ, Seidell JC, Pijl H, Meinders AE. Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity. Obes Res 11: 1147-1154, 2003.
22. Lammers GJ, Pijl H, Iestra J, Langius JA, Buunk G, Meinders AE. Spontaneous food choice in narcolepsy. Sleep 19: 75-76, 1996.
23. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98: 365-376, 1999.
24. López M, Nogueiras R, Tena-Sempere M, Diéguez C. Orexins (hypocretins) actions on the GHRH/somatostatin-GH axis. Acta Physiol (Oxf) 198: 325-334, 2010.
25. Mamelak M. Narcolepsy and depression and the neurobiology of gammahydroxybutyrate. Prog Neurobiol 89: 193-219, 2009.
26. Middelkoop HA, Lammers GJ, Van Hilten BJ, Ruwhof C, Pijl H, Kamphuisen HA. Circadian distribution of motor activity and immobility in narcolepsy: assessment with continuous motor activity monitoring. Psychophysiology 32: 286-291, 1995.
27. Obál F Jr, Krueger JM. The somatotropic axis and sleep. Rev Neurol (Paris) 157: S12-S15, 2001.
28. Obal F Jr, Krueger JM. GHRH and sleep. Sleep Med Rev 8: 367-377, 2004.
29. Okun ML, Giese S, Lin L, Einen M, Mignot E, Coussons-Read ME. Exploring the cytokine and endocrine involvement in narcolepsy. Brain Behav Immun 18: 326-332, 2004.
30. Overeem S, Kok SW, Lammers GJ, Vein AA, Frolich M, Meinders AE, Roelfsema F, Pijl H. Somatotropic axis in hypocretin-deficient narcoleptic humans: altered circadian distribution of GH-secretory events. Am J Physiol Endocrinol Metab 284: E641-E647, 2003.
31. Overeem S, Scammell TE, Lammers GJ. Hypocretin/orexin and sleep: implications for the pathophysiology and diagnosis of narcolepsy. Curr Opin Neurol 15: 739-745, 2002.
32. Pincus SM, Goldberger AL. Physiological time-series analysis: what does regularity quantify? Am J Physiol Heart Circ Physiol 266: H1643-H1656, 1994.
33. Poli F, Plazzi G, Di Dalmazi G, Ribichini D, Vicennati V, Pizza F, Mignot E, Montagna P, Pasquali R, Pagotto U. Body mass indexindependent metabolic alterations in narcolepsy with cataplexy. Sleep 32: 1491-1497, 2009.
34. Ripley B, Overeem S, Fujiki N, Nevsimalova S, Uchino M, Yesavage J, Di MD, Dohi K, Melberg A, Lammers GJ, Nishida Y, Roelandse FW, Hungs M, Mignot E, Nishino S. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 57: 2253-2258, 2001.
35. Salomon F, Cuneo RC, Umpleby AM, Sonksen PH. Glucose and fat metabolism in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 41: 315-322, 1994.
36. Schuld A, Blum WF, Uhr M, Haack M, Kraus T, Holsboer F, Pollmacher T. Reduced leptin levels in human narcolepsy. Neuroendocrinology 72: 195-198, 2000.
37. Schuld A, Hebebrand J, Geller F, Pollmacher T. Increased body-mass index in patients with narcolepsy. Lancet 355: 1274-1275, 2000.
38. Takahara J, Yunoki S, Yakushiji W, Yamauchi J, Yamane Y. Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab 44: 1014-1017, 1977.
39. U.S. Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 25: 42-49, 2002.
40. U.S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 5: 119-123, 2004.
41. Van Cauter E, Leproult R, Plat L. Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. JAMA 284: 861-868, 2000.
42. Van Cauter E, Kerkhofs M, Caufriez A, Van Onderbergen A, Thorner MO, Copinschi G. A quantitative estimation of growth hormone secretion in normal man: reproducibility and relation to sleep and time of day. J Clin Endocrinol Metab 74: 1441-1450, 1992.
43. Van Cauter E, Latta F, Nedeltcheva A, Spiegel K, Leproult R, Vandenbril C, Weiss R, Mockel J, Legros JJ, Copinschi G. Reciprocal interactions between the GH axis and sleep. Growth Horm IGF Res 14, Suppl A: S10-S17, 2004.
44. Van Cauter E, Plat L, Scharf MB, Leproult R, Cespedes S, L'Hermite-Baleriaux M, Copinschi G. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by γ-hydroxybutyrate in normal young men. J Clin Invest 100: 745-753, 1997.
45. Van Cauter E, Plat L, Copinschi G. Interrelations between sleep and the somatotropic axis. Sleep 21: 553-566, 1998.
46. Veldhuis JD. Neuroendocrine control of pulsatile growth hormone release in the human: relationship with gender. Growth Horm IGF Res 8, Suppl B: 49-59, 1998.
47. Vienne J, Bettler B, Franken P, Tafti M. Differential effects of GABAB receptor subtypes, {gamma}-hydroxybutyric Acid, and Baclofen on EEG activity and sleep regulation. J Neurosci 30: 14194-14204, 2010.
48. Weaver TE, Cuellar N. A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy. Sleep 29: 1189-1194, 2006.
49. Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 1: 391-397, 2005.
50. Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebocontrolled study in 228 patients. Sleep Med 6: 415-421, 2005.